[
    [
        {
            "time": "2019-04-30",
            "original_text": "大参林（603233）：业绩超预期，未来门店扩张有望加速【2019年报及2020一季报点评|西南医药朱国广/杜向阳团队】",
            "features": {
                "keywords": [
                    "大参林",
                    "业绩超预期",
                    "门店扩张",
                    "加速",
                    "2019年报",
                    "2020一季报",
                    "西南医药",
                    "朱国广",
                    "杜向阳"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "零售"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "大参林（603233）：业绩超预期，未来门店扩张有望加速【2019年报及2020一季报点评|西南医药朱国广/杜向阳团队】",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]